Haleon Pakistan Limited (PSX: HALEON)

Market Cap	97.29B
Revenue (ttm)	35.41B
Net Income (ttm)	3.57B
Shares Out	117.05M
EPS (ttm)	30.50
PE Ratio	27.25
Forward PE	n/a
Dividend	10.00 (1.19%)
Ex-Dividend Date	Nov 5, 2024

Volume	37,906
Average Volume	51,738
Open	858.00
Previous Close	841.94
Day's Range	800.05 - 858.00
52-Week Range	180.00 - 975.00
Beta	0.61
RSI	44.61
Earnings Date	Apr 25, 2025

About Haleon Pakistan

Haleon Pakistan Limited engages in the research and development, manufacture, marketing, and sale of consumer healthcare products in Pakistan, Africa, Australia, North America, Asia, the Middle East, and Europe. It offers oral health, pain relief, vitamins and mineral supplements, and respiratory health products. The company sells its products under the Panadol, CaC-1000 Plus, Sensodyne, paradontax, Actified, T-Day, ENO, Herbactive, Hydrozole, Qalsium-D, and Voltral Emulgel brands. It also exports its products to the Philippines and Vietnam. Th...

• Industry: Pharmaceutical Preparations
• Founded: 2015
• Employees: 481
• Stock Exchange: Pakistan Stock Exchange
• Ticker Symbol: HALEON

Financial Performance

In 2023, Haleon Pakistan's revenue was 31.61 billion, an increase of 14.91% compared to the previous year's 27.51 billion. Earnings were 995.59 million, an increase of 205.95%.